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Interferons (IFNs) are secreted proteins of the cytokine family that regulate innate and
adaptive immune responses to infection. Although the importance of IFNs in the antiviral
response has long been appreciated, their role in bacterial infections is more complex and
is currently a major focus of investigation. This review summarizes our current knowledge
of the role of these cytokines in host defense against the bacterial pathogen Listeria
monocytogenes and highlights recent discoveries on the molecular mechanisms evolved
by this intracellular bacterium to subvert IFN responses.
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INTRODUCTION
Listeria monocytogenes is a pathogenic Gram-positive bacillus
responsible for a foodborne disease in humans and animals
called listeriosis (Vázquez-Boland et al., 2001). This highly ver-
satile bacterium can be isolated from multiple sources such as
human and animal feces, soil, water, plants and food. As a
common contaminant of fruits, vegetables, seafood, meat and
cheese, it represents a major economic problem for the food
industry. Infection usually originates from ingestion of con-
taminated food (Schlech et al., 1983) and may cause febrile
gastroenteritis in otherwise healthy persons (Ooi and Lorber,
2005). In contrast, in immunocompromised individuals it leads
to a severe invasive disease, which manifests itself as septicemia,
meningitis and encephalitis. In the specific case of pregnant
women, infection may cause fetal loss or neonatal bacteremia and
meningitis. In the United States, incidence of listeriosis ranged
from 2.5 to 3.2 cases per million population between 2004 and
2009 (Cartwright et al., 2013). In France, incidence was 3.9
per million between 2001 and 2008, and increased risk of lis-
teriosis was noticed in people with underlying diseases, such
as chronic lymphocytic leukemia (Goulet et al., 2012). While
relatively rare, listeriosis is among the most deadly foodborne
diseases with mortality rates reaching up to 50% depending on
the clinical manifestations (Lorber, 1997). In addition to the
immunological status of the patient, the clinical outcome of
the disease depends on the pathogenic potential of the infect-
ing bacteria. L. monocytogenes strains of serovars 1/2a, 1/2b, and
4b account for 95% of human cases and serovar 4b alone is
associated to most outbreaks (Swaminathan and Gernersmidt,
2007).
The capacity of L. monocytogenes to survive and multiply
within the gastrointestinal tract is critical for the initial infection,
persistence and transmission. L. monocytogenes is well adapted to
this environment and produces multiple factors to compete with
microbiota and counteract antimicrobial peptides, acidity, hyper-
osmolarity, hypoxia, bile and iron deprivation (Gahan and Hill,
2005). Crossing of the intestinal epithelium is thought to occur
by invasion of enterocytes, in particular goblet cells andM cells
of the Peyer’s patches. Invasion of enterocytes requires the spe-
cific interaction between the Listeria surface protein InlA and its
cellular receptor E-cadherin (Lecuit et al., 2001; Disson et al.,
2008), which can take place at sites of cell extrusion at the tip and
other locations of intestinal villi (Pentecost et al., 2006; Nikitas
et al., 2011). Indeed, as recently shown, upon interaction with
E-cadherin, Listeria preferentially crosses the intestinal barrier
by transcytosis through goblet cells (Nikitas et al., 2011). Entry
through ileal Peyer’s patches viaM cells does not rely on InlA. It
has been reported to require Listeria invasion protein InlB (Chiba
et al., 2011). After translocation, bacteria reach lymph nodes, the
liver and spleen and finally secondary target sites of infection,
including the central nervous system and the placenta.
A remarkable feature of L. monocytogenes is its capacity to
invade non-professional phagocytic cells such as enterocytes,
hepatocytes and trophoblast cells. The exceptional repertoire of
virulence factors necessary for entry, survival and multiplication
has been extensively studied (Camejo et al., 2011; Cossart, 2011).
Expression of many virulence genes relies on the transcriptional
activator PrfA, whose role is pivotal for L. monocytogenes transi-
tion from saprophytic to intracellular lifestyle (Freitag et al., 2009;
Toledo-Arana et al., 2009).
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Elimination of L. monocytogenes is mostly based on the capac-
ity of the host to mount an efficient cellular immune response
to infection (Mackaness, 1962; Shi and Pamer, 2011). In partic-
ular, the fate of infection depends on the level of macrophage
activation and on Listeria ability to counteract bactericidal mech-
anisms of host cells (Shaughnessy and Swanson, 2007; Corr and
O’Neill, 2009; Stavru et al., 2011). Bacterial escape from the
phagosome and avoidance of autophagy for intracytosolic repli-
cation and cell-cell spread have been well characterized. They
have been shown to depend on five major virulence factors:
the secreted pore-forming toxin listeriolysin O (LLO) and two
phospholipases C (PlcA and PlcB) for vacuolar escape, the sur-
face protein ActA for actin-based motility and both ActA and
a surface protein of the internalin family, InlK, for autophagy
evasion (Cossart, 2011; Dortet et al., 2012). Other strategies of
immune escape that lead to the modulation of cytokine expres-
sion occur through a variety of mechanisms. Modifications of L.
monocytogenes peptidoglycan by the N-deacetylase PgdA and the
O-acetyl transferase OatA prevent lysozyme-dependent release of
microbe-associated molecular patterns (MAMPs), activation of
pathogen-recognition receptors (PRRs) and subsequent produc-
tion of pro-inflammatory cytokines (Boneca et al., 2007; Aubry
et al., 2011; Rae et al., 2011). The toxin LLO induces dephos-
phorylation of histone H3 and deacetylation of histone H4,
which correlate with decreased expression of pro-inflammatory
genes, such as the chemokine gene cxcl2 (Hamon et al., 2007).
The secreted internalin InlC inhibits inflammation by inter-
acting with IKK-α, a component of the IκB-kinase complex,
which is essential for NF-κB activation and expression of pro-
inflammatory genes (Gouin et al., 2010). Other evasion mech-
anisms remain to be characterized, such as the control of the
expression of IL-6 by the surface internalin InlH (Personnic
et al., 2010). L. monocytogenes also has the capacity to modulate
interferon (IFN) production during infection. Type I IFN pro-
duction by infected cells can be controlled by Listeria multidrug
efflux pumps MdrM and MdrT, via the secretion of the sec-
ond messenger cyclic-di-AMP (Crimmins et al., 2008; Woodward
et al., 2010; Schwartz et al., 2012). Synthesis of type III IFN has
also recently been shown to be tuned by Listeria nucleomod-
ulin LntA (Lebreton et al., 2011). Our knowledge concerning
the role of the IFN cytokine family during listeriosis has rapidly
expanded in the last few years and will be the focus of this
review.
INTERFERONS
THE IFNs FAMILY
IFNs form a family of proteins secreted by many cell types in
response to infection. They were originally named for their capac-
ity to interfere with viral proliferation (Isaacs and Lindemann,
1957). This diverse family is composed of three groups of
cytokines, namely type I-, type II-, and type III-IFNs, which are
important components of innate immune responses (Table 1).
Type I-IFNs consist of IFN-α, IFN-β, IFN-δ, IFN-ε, IFN-ζ, IFN-
κ, IFN-ν, IFN-τ, and IFN-ω (Levy et al., 2011). Type II-IFN is
composed of a single cytokine, IFN-γ (Pestka et al., 2004). Type
III-IFNs are IFN-λ1, IFN-λ2, and IFN-λ3 (formerly IL-29, IL-
28A, and IL-28B) and IFN-λ4 (Kotenko, 2011; Prokunina-Olsson
et al., 2013). Type I- and type III-IFNs have similar signal
transduction systems (see below) and are phylogenetically closer
from each other than type II-IFN (Pestka et al., 2004).
Sequence conservation and chromosome location suggest that
type I-IFN genes evolved from a single ancestor through duplica-
tion. However, the extent of type I-IFN gene diversification varies
greatly depending on the species (Pestka et al., 2004). Generally,
a single gene encodes the type I-IFN in fish. In contrast, multi-
ple gene duplications and diversification led to the emergence of
sub-types of type I-IFNs in mammals (Table 1). Gene duplication
varies also within each sub-type. A single IFN-β gene is found in
the human andmouse genomes (Decker et al., 2005; Honda et al.,
2006; Durbin et al., 2013). In contrast 13 IFN-α genes and one
pseudogene and 14 IFN-α genes and three pseudogenes are found
in the human and mouse genomes, respectively (van Pesch et al.,
2004; Durbin et al., 2013). A single gene encodes type II-IFN and
four genes encode type III-IFNs in human (Decker et al., 2005;
Levy et al., 2011). Of note, IFN-λ1 and IFN-λ4 are pseudogenes
in mice, which prevents the study of these cytokines in this animal
model (Table 1) (Fox et al., 2009).
IFN ACTIVITIES: GENERAL OVERVIEW
IFNs are important components of the immune system, which
generally trigger cellular protective defenses in response to infec-
tion or tumor formation. Type-II IFN (IFN-γ) is a paradigm for
this, being an important mediator of innate and adaptive immune
responses with a key role in clearance of viral and bacterial
pathogens and in tumor control. IFN-γ was first described as an
antiviral protein (Wheelock and Sibley, 1965), but is now known
to exhibit broader biological activities, non-redundant with that
of other types of IFNs. The crucial role of IFN-γ in immunity
to infection is reflected by the phenotype of mice lacking the
IFN-γ receptor or the IFN-γ gene, which are highly suscepti-
ble to Mycobacterium bovis BCG infection (Dalton et al., 1993;
Kamijo et al., 1993). Genetic deficiencies resulting in the loss of
IFN-γ production or signaling in mice lead to increased suscep-
tibility to infections by other intracellular pathogens, such as L.
monocytogenes (see below), Salmonella typhimurium and some
viruses (Huang et al., 1993; Harty and Bevan, 1995; Jouanguy
et al., 1999). These defects also lead to the loss of tumor con-
trol (Kaplan et al., 1998). Patients with deficiencies in the IFN-γ
pathway, for instance by mutation in the gene for the IFN-γ
receptor 1, are characterized by severe infections with viruses and
intracellular bacteria including L. monocytogenes, Salmonella sp.
and mycobacteria (Jouanguy et al., 1996; Newport et al., 1996;
Roesler et al., 1999; van de Vosse et al., 2009). IFN-γ mediates
macrophage activation, i.e., increased phagocytosis and produc-
tion of pro-inflammatory cytokines, of microbicidal reactive oxy-
gen and nitrogen species, leading to clearance of intracellular
pathogens (Schoenborn and Wilson, 2007). In addition, IFN-γ
controls differentiation of T cells in Th1 effector cells, antigen
processing and presentation by antigen-presenting cells, which
participate to cellular immunity against intracellular pathogens
(Schroder, 2003; Hu and Ivashkiv, 2009). The immunostimu-
latory and immunomodulatory properties of IFN-γ have ther-
apeutic implications. Indeed, IFN-γ is used in patients with
chronic granulomatous disease to reduce infection and mortality,
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Table 1 | The interferon family.
Type ST* Human** Mouse** Source Target Receptor Signaling
I α 189aa-G*** 189aa-G*** Ubiquitous Ubiquitous IFNAR1 JAK1
β 187aa-GP 182aa-GP IFNAR2 TYK2
δ – – STAT1
ε 208aa 192aa STAT2
ζ – 182aa-G
κ 207aa 199aa
ν Pseudogene –
τ – –
ω 195aa-G –
II γ 166aa-G 155aa-G NK, NKT, T Ubiquitous IFNγR1 JAK1
APC, B IFNγR2 JAK2
STAT1
III λ1 200aa-G Pseudogene Ubiquitous Epithelial cells, IFNLR1 JAK1
λ2 200aa 193aa-G Hepatocytes IL10R2 TYK2
λ3 196aa 193aa STAT1
λ4 179aa Pseudogene STAT2
*Subtypes.
**Protein length in amino-acids and protein modifications (G: glycosylation, P: phosphorylation).
***13 genes and a pseudogene in the human genome, 14 genes and three pseudogenes in the mouse genome.
although the clinical benefit has not been demonstrated in all
studies (Holland, 2010).
Type I-IFNs are produced in responses to viruses, many bac-
teria and parasites. However, in contrast to type II IFNs, these
cytokines are not always protective against bacterial infections.
Indeed, the role of type I-IFNs in response to bacterial infec-
tion is complex and depends on the microorganism (Decker
et al., 2005; Monroe et al., 2010; Carrero, 2013). They contribute
to resistance of the host against infection by extracellular bac-
teria, such as Escherichia coli, Helicobacter pylori, Streptococcus
agalactiae and S. pneumoniae (Mancuso et al., 2007; Watanabe
et al., 2010). In contrast, they are associated with suppression of
innate immune responses and increased susceptibility of the host
to infection by L. monocytogenes (see below), Brucella abortus,
Chlamydia muridarum, Francisella novicida, Salmonella enterica,
Staphylococcus aureus, and Yersinia pestis (Auerbuch et al., 2004;
Carrero et al., 2004; O’Connell et al., 2004; Qiu et al., 2008;Martin
et al., 2009; Henry et al., 2010; de Almeida et al., 2011; Patel
et al., 2012; Robinson et al., 2012; Archer et al., 2014). These
different effects on infection are likely linked to the wide range
of cellular responses induced by their downstream effectors, the
products of IFN-stimulated genes (ISGs) (Schoggins et al., 2011).
Although Type I-IFNs have long been known to induce antivi-
ral response in the infected host (Isaacs and Lindemann, 1957),
they can also induce apoptosis, autophagy, differentiation and
migration, inhibit proliferation as well as angiogenesis and medi-
ate cellular damage, inflammation or autoimmunity (Trinchieri,
2010). As a result, type I-IFNs have a therapeutic potential that
can be used to treat tumors and viral infections (Pestka, 2007;
Heim, 2013; Wilson and Brooks, 2013), while being detrimental
for the host in response to a subset of pathogens.
Type III-IFNs have been discovered in 2003 (Kotenko et al.,
2003; Sheppard et al., 2003) and their activities have been less
extensively characterized than those of type I- and type II-IFNs.
However, several studies suggest that type I and type III-IFNs
share common biological activities (Levy et al., 2011; Zheng et al.,
2013). Although type III-IFNs respond to different stimuli, use
different receptors and are not always expressed by the same cells
as type I IFNs (see below), engagement of type I- and type III-
IFN receptors leads to similar transcriptional responses. Like type
I-IFNs, type III-IFNs have been involved in antiproliferative and
antiviral responses (Iversen and Paludan, 2010; Mordstein et al.,
2010; Durbin et al., 2013; Hamming et al., 2013). Recently, type
III-IFNs have been shown to be induced in response to bacterial
pathogens, but their downstream effects are not yet characterized
(Pietilä et al., 2010; Lebreton et al., 2011; Bierne et al., 2012).
ACTIVATION OF IFNs
Transcription of IFN genes is induced rapidly in response to
microbial infection. Type I-IFNs can be produced by all cells,
while type III-IFNs are secreted by specific cell types, including
dendritic and epithelial cells. Type I- and type III-IFNs activation
is initiated by detection of MAMPs by PRRs such as endoso-
mal transmembrane Toll-like receptors and cytosolic receptors
(Stetson and Medzhitov, 2006; Monroe et al., 2010). Upon recog-
nition of MAMPs, PRRs trigger diverse signaling pathways that
involve adaptor proteins and cytosolic or organelle-bound pro-
tein scaffolds activating kinases converging to phosphorylation of
transcription factors and their subsequent translocation into the
nucleus (Figure 1). IRF1, IRF3, IRF4, IRF5, IRF7, and IRF8 are
important for transcription of the IFN-α genes, with IRF7 con-
sidered as the master regulator of IFN-α response (Honda et al.,
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FIGURE 1 | Activation of type I- and type III-IFNs by infection. (1) Cells
detect pathogens by membrane-bound PRRs of the TLR family, which trigger
the IFN response. Infection of cells with extracellular Gram-negative bacteria
leads to activation of TLR4/CD14/MD2 by LPS. Following TLR4 ligation, IRF3
is activated via the adaptors TRAM and TRIF, and TBK1. (2) Intracellular
bacteria and viruses are recognized by TLRs located in the endosome. TLR2,
TLR3, TLR7/8, and TLR9 detect lipoproteins, dsRNA, ssRNA, and
unmethylated CpG DNA, respectively. Engagement of the receptors leads to
the induction of MyD88- and TRIF-dependent pathways involving IKK-, TBK1-,
and MAPK-mediated activation of NF-κB, IRF3, IRF7, and AP1, ultimately
resulting in transcriptional activation of IFN genes. (3) Infection of cells leads
to the release of cyclic-di-nucleotides (c-di-XMP) and nucleic acids (RNA in
red, DNA in blue) in the cytosol that signal the presence of microbes and
induce expression of interferons. Cyclic-di-nucleotides secreted by bacteria,
e.g., through multidrug resistance MdrT and MdrM in Listeria, can activate
the protein STING directly and via the cytosolic sensor DDX41. Cytosolic DNA
is recognized by DDX41, DAI, cGAS, and IFI16. cGAS converts dsDNA to
cGAMP, which stimulates STING. RNA polymerase III (PolIII) can convert
cytosolic AT-rich dsDNA to uncapped 5′-triphosphate RNA that, as ssRNA, is
sensed by RIGI. Another cytosolic RNA sensor, MDA5, and RIGI signal via the
mitochondrial adaptor MAVS and STING. Activated STING recruits TBK1,
which phosphorylates transcription factors IRF3 and IRF7. Upon activation,
IRFs translocate to the nucleus where they bind to the promoter of type I IFN
genes. Bacterial RNA and DNA additionally activate the cytosolic sensor
LRRFIP1 that stimulates β-catenin phosphorylation and nuclear translocation
where it binds to IRF3, recruits the histone acetyltransferase p300 to the
enhanceosome leading to IFNβ transcription. Gray font and arrows: general
infection pathways, bold black font and arrows: Listeria infection pathways.
Red strands, RNA; blue strands, DNA. AP1, activator
(Continued)
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FIGURE 1 | Continued
protein-1; CD14, cluster of differentiation 14; c-di-XMP, cyclic-di-nucleotide;
cGAMP, cyclic-GMP-AMP; cGAS, cGAMP synthase; DAI, DNA-dependent
activator of IFN-regulatory factors; DDX41, DEAD
(aspartate-glutamate-alanine-aspartate)-box polypeptide 41; ER, endoplasmic
reticulum; IFI16, IFN-inducible protein 16; IKK, IκB kinases; IRAK, interleukin-1
receptor-associated kinase; LP, lipoprotein; LPS, lipopolysaccharide; LRRFIP1,
leucine-rich repeat flightless-interacting protein 1; MAM, mitochondria
associated ER membranes; MAPK, mitogen-activated protein kinase; MAVS,
mitochondrial antiviral signaling; MD2, myeloid differential protein-2; MDA5,
melanoma differentiation-associated gene 5; MyD88, myeloid differentiation
factor 88; NF-κB, nuclear factor of kappa light polypeptide gene enhancer in
B-cells; PolIII, RNA polymerase III; RIGI, retinoic acid inducible gene I; STING,
stimulator of IFN genes; TBK1, TANK-binding kinase-1; TIRAP, TIR
domain-containing adapter protein; TLR, Toll-like receptor; TRAM, TRIF-related
adaptor molecule; TRIF, TIR domain-containing adaptor inducing IFN-β.
2005; Tailor et al., 2007; Levy et al., 2011). Regulation of the IFN-
β gene is more complex. Activated IRF3, IRF7, AP-1, and NF-κB
bind to the enhancer/promoter regions of the IFN-β gene and
participate to the formation of the enhanceosome, which alters
chromatin structure and allows transcription (Panne et al., 2007;
Panne, 2008). In contrast, IRFs and NF-κB independently activate
transcription of type III-IFN genes (Iversen and Paludan, 2010).
Regulation of the IFN-γ gene expression is different from that
of type I and type III-IFN genes. NK cells and NKT cells are
effectors of the innate immune response and primary sources of
IFN-γ. Mature NK and NKT cells quickly react to infection by
inducing IFN-γ secretion. Upon recognition of ligands expressed
on infected cells, NK cell activating-receptors trigger signaling
cascades involving adaptor proteins and protein tyrosine kinases
leading to activation of Ras/Sos, PLC-γ and MAPK pathways and
induction of IFN-γ production (Schoenborn and Wilson, 2007).
In addition to receptors, IL-2, IL-15, IL-12, IL-18, and type I-
IFNs also contribute to induction of IFN-γ production by NK
cells (Newman and Riley, 2007; Schoenborn and Wilson, 2007;
Marçais et al., 2013). Similarly, IL-12 and IL-18 induce IFN-γ pro-
duction by NKT cells (Godfrey and Berzins, 2007). In NK and
NKT cells, the IFN-γ gene locus is transcriptionally permissive
within accessible chromatin and allows rapid IFN-γ expression
upon activation of transcription factors, such as AP-1, NF-κB,
STAT4, and T-bet (Glimcher et al., 2004; Schoenborn andWilson,
2007; Lazarevic et al., 2013). In addition, naive CD4 and CD8 T
cells can differentiate into Th1 CD4 effector T cells and CD8 cyto-
toxic T lymphocytes capable of IFN-γ secretion (Wilson et al.,
2009). IFN-γ production by CD4 and CD8 T cells depends on
IL-12, IL-18 and IFN-γ itself and share many signaling pathways
with NK cells. Multiple transcription factors act at the IFN-γ
promoter, e.g., AP-1, ATF-2/c-Jun, C/EBP, Eomes, Ets-1, NFAT,
NF-κB, Runx3, STATs and T-bet (Schoenborn and Wilson, 2007;
Samten et al., 2008; Wilson et al., 2009; Lazarevic et al., 2013).
Moreover, distal regulatory elements modify the chromatin and
remodel the IFN-γ gene locus to facilitate IFN-γ production
(Wilson et al., 2009).
IFN RECEPTORS AND SIGNAL TRANSDUCTION
IFNs are rapidly secreted upon infection and then bind to their
receptors on the surface of target cells (Table 1). Type I-IFNs bind
the ubiquitous IFNAR receptor, which consists of two chains,
IFNAR1 and IFNAR2 (Piehler et al., 2012). Type III-IFNs bind
and signal through a different receptor complex, made of two
chains: IFNLR1 (also known as IL-28Rα) and IL10R2. This recep-
tor is expressed primarily by epithelial cells and hepatocytes
(Iversen and Paludan, 2010). Thus, the physiological roles of
type I- and type III-IFNs are distinct because of the different
distribution of their receptors in tissues, type III-IFNs acting pre-
dominantly at mucosal surfaces (Mordstein et al., 2010; Durbin
et al., 2013). Type I- and type III-IFNs use different receptors but
trigger the same JAK-STAT signal transduction cascade involv-
ing TYK2, JAK1, STAT1, and STAT2 albeit with different kinetics
(Figure 2) (Marcello et al., 2006). Ultimately, STAT1, STAT2, and
IRF9 form a transcription factor complex, referred to as ISGF3,
which translocates to the nucleus and binds to IFN-stimulated
responsive elements (ISRE) in the promoter of ISGs (Schindler
et al., 2007). Type II-IFN, uses a heterodimeric receptor con-
sisting of IFNγR1 and IFNγR2 chains, expressed by many cell
types (Bach et al., 1997). IFN-γ activates JAK1, JAK2 and STAT1,
leading to transcription of genes bearing a γ-activation sequence
(GAS) in their promoter (Figure 2) (Schindler et al., 2007).
IFNs AND LISTERIA INFECTION
INDUCTION OF IFNs IN RESPONSE TO LISTERIA INFECTION
An initial innate immune response is triggered when Listeria
MAMPs activate PRRs of host cells such as epithelial cells and
macrophages (Figure 1). Infection induces a robust type I-IFN
response. In mice, macrophages have been identified as the major
source of IFN-β (Stockinger et al., 2009). In vitro, IFN-β pro-
duction by bone-marrow-derived murine macrophages has been
shown to require bacterial escape from the phagosome and acti-
vation of cytosolic surveillance pathways (O’Riordan et al., 2002).
Induction of IFN-β depends on the adaptor protein STING and
the cytosolic PRR DDX41, which are activated by bacterial sec-
ondary messengers c-di-AMP and c-di-GMP and by bacterial
DNA (Woodward et al., 2010; Burdette et al., 2011; Sauer et al.,
2011; Parvatiyar et al., 2012; Archer et al., 2014). STING is a
direct receptor for cyclic-dinucleotides, including the cellular sec-
ond messenger cyclic GMP-AMP (cGAMP) which is produced by
the cytosolic sensor cGAMP synthase (cGAS) upon interaction
with microbial DNA (Ablasser et al., 2013; Gao et al., 2013; Wu
et al., 2013; Sun et al., 2013; Schoggins et al., 2014). Interestingly,
type I-IFN production requires activation of the RIG-I helicase
by Listeria RNA in non-immune cells lacking a functional STING
signaling pathway (Abdullah et al., 2012; Hagmann et al., 2013).
Another cytosolic PRR, the leucine-rich repeat-containing pro-
tein LRRFIP1, has also been implicated in IFN-β production by
mouse primary peritoneal macrophages in response to Listeria
infection, possibly by sensing double stranded DNA and RNA
(Yang et al., 2010). While production of IFN-β in response to
Listeria infection is independent from TLRs in bone-marrow-
derived macrophages (McCaffrey et al., 2004; Stockinger et al.,
2004; O’Connell et al., 2005), TLR-2 contributes significantly
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 5
Dussurget et al. Listeria and interferons
FIGURE 2 | Signal transduction by the type I, type II and type III IFN
receptors. Engagement of type I and type III IFNs by their respective
receptors, IFNAR1/IFNAR2 and IFNLR1/IL10R2, triggers phosphorylation of
JAK1/TYK2 kinases that activate STAT1 and STAT2. Phosphorylated
STAT1/STAT2 heterodimers bind IRF9 forming the ISGF3 complex, which
translocates to the nucleus where it induces expression of genes with
ISRE-dependent promoters. Engagement of type II IFN by the
IFNγR1/IFNγR2 receptor induces phosphorylation of JAK1/JAK2 kinases that
activate STAT1. Phosphorylated STAT1 homodimers translocate to the
nucleus and induces expression of genes with GAS-dependent promoters.
CXCL, CXC chemokine ligand; DUOX, dual oxidase; GAS, gamma-IFN
activated site; GBP, guanylate-binding protein; IDO, indoleamine
2,3-dioxygenase; IFITM, IFN-induced transmembrane protein; IRF9,
IFN-regulatory factor 9; ISG, IFN-stimulated gene; ISGF3, IFN-stimulated
gene factor 3; ISRE, IFN-stimulated response element; JAK, Janus activated
kinase; MX, myxovirus resistance; NOS2, nitric oxide synthase 2; NOX,
NADPH oxidase; OAS, oligoadenylate synthetase; STAT, signal transducer and
activator of transcription; TRIM, tripartite motif; TYK2, tyrosine kinase 2.
to IFN-β secretion by peritoneal macrophages, suggesting that
specific macrophage populations have evolved different recog-
nition strategies in response to Listeria infection (Aubry et al.,
2012).
Listeria infection has recently been shown to induce type III-
IFN gene expression in cells of epithelial origin, such as intestinal
and trophoblast cells and hepatocytes (Lebreton et al., 2011;
Bierne et al., 2012). Similar to type I-IFN, type III-IFN induction
is triggered by intracellular Listeria (Bierne et al., 2012).
Listeria infection also triggers a rapid and robust IFN-γ
response. After intravenous infection of mice with L. monocy-
togenes, NK and T cells are the main sources of IFN-γ (Thale
and Kiderlen, 2005; Bou Ghanem et al., 2009). IFN-γ produc-
ing V1δ+-γδ T cells are other murine immune cells induced at
an early stage of Listeria infection in mice inoculated intraperi-
toneally (Hamada et al., 2008). Using oral infection of mice, the
natural route of infection in permissive hosts, L. monocytogenes
has been shown to induce IFN-γ production by intraepithe-
lial lymphocytes of the small intestine (Okamoto, 1994). More
recently, human E-cadherin (hEcad) expressing mice, a mouse
line permissive for Listeria oral infection (Lecuit et al., 2001),
were used to study cells involved in intestinal mucosal immu-
nity. Infection induced IFN-γ production in NK cells of the small
intestine (Reynders et al., 2011).
ROLE OF IFNs DURING LISTERIA INFECTION
The production of IFN-γ by immune cells promotes bacterial
clearance and is thus critical in controlling primary L. mono-
cytogenes infections (Zenewicz and Shen, 2007). Injection of
neutralizing monoclonal anti-IFN-γ antibodies in mice infected
intraperitoneally with L. monocytogenes inhibits macrophage acti-
vation and increases the mortality rate (Buchmeier and Schreiber,
1985). In addition, resistance of IFN-γ gene or IFN-γ receptor
knock-out mice infected intravenously with L. monocytogenes is
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severely impaired (Huang et al., 1993; Harty and Bevan, 1995).
Recent work using cell-type specific inactivation of STAT1 in
mice elegantly demonstrated the key role of IFN-γ and STAT1
in macrophage activation and clearance of Listeria (Kernbauer
et al., 2012). Interestingly, the role of STAT1 was extremely differ-
ent after infection of immunized mice. STAT1 signaling in T cells
and dendritic cells was critical for adaptive immunity to Listeria,
while IFN-γ-activated macrophages were not essential anymore
once memory cells were produced. Upon oral infection of hEcad
mice with Listeria, IFN-γ contributes to the control of bacterial
burden in the intestine and of bacterial dissemination to other
organs. For instance, blocking IFN-γ with neutralizing antibod-
ies increases Listeria load in the small intestine, the mesenteric
lymph nodes and in the spleen of mice infected orally (Reynders
et al., 2011).
In contrast to IFN-γ, type I-IFN is beneficial to L. monocyto-
genes. Mice lacking type I-IFN receptor or IRF3 are more resistant
to Listeria intraperitoneal or intravenous infection (Auerbuch
et al., 2004; Carrero et al., 2004; O’Connell et al., 2004; Garifulin
et al., 2007; Jia et al., 2009). The role of type I-IFNs in increasing
host susceptibility could be explained by modulation of compo-
nents of the immune response involved in controlling bacterial
growth such as induction of T cell apoptosis, resulting in greater
IL-10 secretion by phagocytic cells, in turn dampening the innate
immune response (Carrero and Unanue, 2006), the downregu-
lation of IFN-γR (Rayamajhi et al., 2010; Kearney et al., 2013),
or neutrophil recruitment (Brzoza-Lewis et al., 2012). As shown
recently, STING-dependent activation of type I-IFN reduces the
adaptive immune response to L. monocytogenes (Archer et al.,
2014). In contrast, recent studies showed that type I-IFNs can also
play a beneficial role for the host during Listeria infection, point-
ing to the infection route and the timing of type I-IFN production
as determinative factors (Pontiroli et al., 2012; Kernbauer et al.,
2013).
Interestingly, different strains of L. monocytogenes have been
shown to vary greatly in their capacity to induce IFN-β (Reutterer
et al., 2008; Schwartz et al., 2012). The LO28 strain hyperin-
duces IFN-β (Reutterer et al., 2008). This strain bears a non-
functional BrtA (also named TetR), the transcriptional repressor
of the multidrug efflux pump MdrT (Schwartz et al., 2012;
Yamamoto et al., 2012). In Listeria, MdrT allows secretion of c-
di-AMP, which triggers IFN-β. Thus, derepression of MdrT in the
LO28 strain promotes IFN-β production. Of note, high expres-
sion of MdrT in LO28 correlates with both induction of IFN-β
and lower virulence. Another Listeria multidrug resistance trans-
porter, MdrM, has been involved in the stimulation of IFN-β
production, possibly by secreting c-di-AMP (Crimmins et al.,
2008; Woodward et al., 2010; Witte et al., 2012).
The role of type III-IFNs during listeriosis remains to be deter-
mined. Since Listeria colonizes several tissues of epithelial origins,
such as the liver, intestine and placenta, it is tempting to spec-
ulate that IFN-λs play a role in the interaction of Listeria with
epithelia. However, a prerequisite to address this question is the
establishment of a new animal model, i.e., a mouse line express-
ing a human E-cadherin, thus permissive for Listeria infection
of epithelia (Lecuit et al., 2001) and impaired in type III-IFN
responses, such as IL28Rα knockoutmice (Mordstein et al., 2010).
One should keep in mind that the mouse model is not optimal
to address the role of type III-IFN in human listeriosis. Indeed,
IFN-λ1 is a pseudogene in mice, while human cells produce this
cytokine upon infection with L. monocytogenes. In addition, the
type III-IFN receptor is expressed at very low levels in the mouse
liver and the IFN-λ response of the mouse liver is very weak
(Mordstein et al., 2010). In line with this, it has been recently
shown that mouse hepatocytes, in contrast to human hepatocytes,
are not responsive to IFN-λ (Hermant et al., 2014).
ROLE OF IFN-STIMULATED GENES DURING LISTERIA INFECTION
The beneficial or detrimental effects of IFNs on Listeria infection
rely on the functional properties of their downstream effec-
tors. Indeed, IFNs elicit expression of hundreds of interferon-
stimulated genes (ISGs), which encode proteins involved in a
broad range of cellular functions (reviewed in MacMicking,
2004). However, while about 2,000 ISGs have been identified so
far (Rusinova et al., 2012), their functions in immunomodu-
lation remain to be characterized. To date, the contribution of
interferon-induced proteins on Listeria infection has mostly been
studied in the context of the IFN-γ pathway.
The antilisterial activity of IFN-γ in phagocytic cells involves
induction of oxidative and nitrosative defences, via increased
expression of enzymes that control production of reactive oxy-
gen and nitrogen species, such as NOX2/CYBB, DUOX2, and
iNOS/NOS2 (MacMicking, 2012). These enzymes play an impor-
tant role in protecting infected cells against Listeria cytoinva-
sion (Myers et al., 2003; Lipinski et al., 2009). The assembly
of these enzymes requires IFN-γ–inducible guanosine triphos-
phatases (GTPases) of the Gbp (guanylate binding protein) family
(Boehm et al., 1998), which not only participate to oxidative
pathways but also regulate autophagy (Kim et al., 2011). Several
Gbps have been shown to protect cells from Listeria infec-
tion by coordinating a potent oxidative and vesicular trafficking
program (Kim et al., 2011). IFN-γ also induces the expres-
sion of many nuclear genes encoding mitochondrial respiratory
chain machinery, via activation of the nuclear receptor ERRα
(estrogen-related receptor α). ERRα contributes to mitochon-
drial ROS production and efficient clearance of L. monocytogenes
(Sonoda et al., 2007). A family of IFN-γ-induced chemokines
(CXCL9, CXCL10, CXCL11) displays direct antimicrobial activ-
ity against L. monocytogenes (Cole et al., 2001). In dendritic
cells, one of the IFN-γ-associated ISGs is the immunoregula-
tory enzyme indoleamine 2,3-dioxygenase (IDO), a key enzyme
of the tryptophan metabolism. IDO is proposed to play a role
in the containment of Listeria within granulomatous struc-
tures, thus avoiding massive T cell activation (Popov et al.,
2006).
The function of type I IFN-associated ISGs in Listeria infec-
tion is less documented. Zwaferink et al. have observed that
upregulation of iNOS/NOS2 by IFN-β promotes necrotic death
of macrophages (Zwaferink et al., 2007). Additionally, several
interferon-inducible proteins belong to inflammasomes; thus,
type I IFN may potentiate inflammasome activation and cell
death by pyroptosis (Malireddi and Kanneganti, 2013). Yet, the
link between these effectors and the observed harmful effects
of type I IFNs on the host is still unclear. Likewise, the role of
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effectors induced by type III IFNs in Listeria infection of epithelia
is not understood.
Of interest, a subset of ISGs is amongst the most induced genes
in the intestinal tissue of gnotobiotic humanized mice infected
orally with L. monocytogenes (Archambaud et al., 2012). However,
which type of IFNs triggers this response and for which func-
tion on the intestinal mucosa remain to be explored. In addition,
IFN-independent pathways may contribute to expression of these
ISGs.
SUBVERSION OF IFN RESPONSES BY LISTERIA
Listeria has evolved several mechanisms to avoid immune detec-
tion and evade IFN responses. It has been demonstrated that
deacetylation of Listeria peptidoglycan by the deacetylase PgdA
confers resistance to host lysozyme, thus preventing release of
MAMPs, such as DNA, RNA and lipopeptides, that trigger IFN-
β production (Boneca et al., 2007). Listeria pgdA mutants are
rapidly killed in murine macrophages, which produce lysozyme,
and induce a strong secretion of IFN-β compared to wild-
type Listeria. The role of PgdA is not limited to the control
of type I-IFN production as a pgdA mutant hyperinduces pro-
inflammatory cytokines as well. Modification of peptidoglycan by
PgdA is an extremely efficient mechanism of immune escape used
by Listeria, which correlates with its critical role in virulence.
Remarkably, Listeria has evolved a sophisticated strategy to
modulate, either negatively or positively, the expression of ISGs
in epithelial cells, by targeting a chromatin-repressive complex,
BAHD1 (Bierne et al., 2009; Lebreton et al., 2011, 2012). Indeed,
Listeria infection promotes, albeit via an unknown mechanism,
the targeting of BAHD1 at the promoter of a set of ISGs, thereby
downregulating type I- and type III-IFN responses. On the other
hand, Listeria can produce a nucleomodulin, LntA, which when
secreted by intracellular bacteria, enters the nucleus of infected
cells, binds BAHD1 and inhibits its function (Lebreton et al.,
2012, 2014). Thus, LntA stimulates IFN responses. Consistent
with the presence of HDAC1/2 in the BAHD1-associated com-
plex, the level of acetylation of lysine 9 on histone H3, which is a
mark of active chromatin, increases at the promoters of ISGs in
the presence of LntA. When, in which host conditions, and how
LntA targets BAHD1 specifically at ISGs remains an open ques-
tion. The LntA-mediated stimulation of type III-IFN responses
might support localized pro-bacterial conditions, as was proposed
for IFN-I responses.
CONCLUDING REMARKS
We have an extensive knowledge of the molecular and cellu-
lar mechanisms involved in Listeria-host interactions. Yet, our
understanding of the immune response to Listeria, and more
specifically the role IFNs and of their downstream effectors, is far
from complete and often relies on studies performed in cultured
cells or in mice. However, murine and human listeriosis differ in
many aspects (Lecuit, 2007; Hoelzer et al., 2012). For instance,
E-cadherin, the major receptor for Listeria in epithelial cells, is
not functional for Listeria uptake in the mouse. Thus, the route
of entry of Listeria is not strictly the same in mice and humans.
Moreover, ISGs induced in response to infection are not iden-
tical in mice and humans. Additionally, murine hepatocytes do
not respond to type III-IFNs (Hermant et al., 2014), precluding
the study of these IFNs during infection by human hepatotropic
pathogens, such as L. monocytogenes. Altogether, species-specific
differences provide limits to the use of mouse models in char-
acterizing IFN pathways engaged during Listeria infection in
humans, especially in key epithelial organs such as the gut, liver
and placenta. It will be important to perform future studies using
adapted animal models, such as humanized mice permissive to
oral infection or transgenic mice with human xenografts (Walters
et al., 2006), since the effect of type I-IFN on Listeria infection
depends on the route and time of infection (Pontiroli et al., 2012;
Kernbauer et al., 2013) and type III-IFN requires bacterial inter-
action with epithelia (Bierne et al., 2012). Finally, numerous ISGs
are induced upon Listeria infection in vitro, but the relevant ISGs
and their cellular functions remain to be identified. Validation
of ISGs identified in cultured cells in adequate in vivo models
or deduced from analyses of patient samples, will be required
to address the complex role of IFNs and bacterial subversion
strategies and provide new insights into Listeria pathogenesis.
ACKNOWLEDGMENTS
The authors declare no conflict of interest. The authors’ work has
been supported in part by the Institut Pasteur, Inserm, INRA,
Université Paris-Diderot, LabEx IBEID, ANR (Grant EPILIS),
French Ligue Nationale contre le Cancer, Fondation Louis-
Jeantet, Fondation Le Roch, and European Research Council
(Advanced Grant Award 233348 to Pascale Cossart). Pascale
Cossart is an international research scholar of the HowardHughes
Medical Institute.
REFERENCES
Abdullah, Z., Schlee, M., Roth, S., Mraheil, M. A., Barchet, W., Böttcher, J. B.
O., et al. (2012). RIG-I detects infection with live Listeria by sensing secreted
bacterial nucleic acids. EMBO J. 31, 4153–4164. doi: 10.1038/emboj.2012.274
Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., et al.
(2013). cGAS produces a 2′-5′-linked cyclic dinucleotide second messenger that
activates STING. Nature 498, 380–384. doi: 10.1038/nature12306
Archambaud, C., Nahori, M.-A., Soubigou, G., Bécavin, C., Laval, L., Lechat, P.,
et al. (2012). Impact of lactobacilli on orally acquired listeriosis. Proc. Nat. Acad.
Sci. U.S.A. 109, 16684–16689. doi: 10.1073/pnas.1212809109
Archer, K. A., Durack, J., and Portnoy, D. A. (2014). STING-dependent type I IFN
production inhibits cell-mediated immunity to Listeria monocytogenes. PLoS
Pathog. 10:e1003861. doi: 10.1371/journal.ppat.1003861
Aubry, C., Corr, S. C., Wienerroither, S., Goulard, C., Jones, R., Jamieson, A. M.,
et al. (2012). Both TLR2 and TRIF contribute to interferon-β production during
Listeria infection. PLoS ONE 7:e33299. doi: 10.1371/journal.pone.0033299
Aubry, C., Goulard, C., Nahori, M.-A., Cayet, N., Decalf, J., Sachse, M., et al.
(2011). OatA, a peptidoglycan O-acetyltransferase involved in Listeria mono-
cytogenes immune escape, is critical for virulence. J. Infect. Dis. 204, 731–740.
doi: 10.1093/infdis/jir396
Auerbuch, V., Brockstedt, D., Meyer-Morse, N., O’Riordan, M., and Portnoy, D.
A. (2004). Mice lacking the type I interferon receptor are resistant to Listeria
monocytogenes. J. Exp. Med. 200, 527–533. doi: 10.1084/jem.20040976
Bach, E. A., Aguet, M., and Schreiber, R. D. (1997). The IFN gamma receptor: a
paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591.
doi: 10.1146/annurev.immunol.15.1.563
Bierne, H., Tham, T. N., Batsche, E., Dumay, A., Leguillou, M., Kerneis-Golsteyn,
S., et al. (2009). Human BAHD1 promotes heterochromatic gene silencing. Proc.
Natl. Acad. Sci. U.S.A. 106, 13826–13831. doi: 10.1073/pnas.0901259106
Bierne, H., Travier, L., Mahlakõiv, T., Tailleux, L., Subtil, A., Lebreton, A., et al.
(2012). Activation of type III interferon genes by pathogenic bacteria in infected
epithelial cells and mouse placenta. PLoS ONE 7:e39080. doi: 10.1371/jour-
nal.pone.0039080
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 8
Dussurget et al. Listeria and interferons
Boehm, U., Guethlein, L., Klamp, T., Ozbek, K., Schaub, A., Fütterer, A., et al.
(1998). Two families of GTPases dominate the complex cellular response to
IFN-gamma. J. Immunol. 161, 6715–6723.
Boneca, I. G., Dussurget, O., Cabanes, D., Nahori, M.-A., Sousa, S., Lecuit, M., et al.
(2007). A critical role for peptidoglycanN-deacetylation in Listeria evasion from
the host innate immune system. Proc. Natl. Acad. Sci. U.S.A. 104, 997–1002. doi:
10.1073/pnas.0609672104
Bou Ghanem, E. N., McElroy, D. S., and D’Orazio, S. E. F. (2009). Multiple mech-
anisms contribute to the robust rapid gamma interferon response by CD8+ T
cells during Listeria monocytogenes infection. Infect. Immun. 77, 1492–1501. doi:
10.1128/IAI.01207-08
Brzoza-Lewis, K. L., Hoth, J. J., and Hiltbold, E. M. (2012). Type I inter-
feron signaling regulates the composition of inflammatory infiltrates upon
infection with Listeria monocytogenes. Cell. Immunol. 273, 41–51. doi:
10.1016/j.cellimm.2011.11.008
Buchmeier, N. A., and Schreiber, R. D. (1985). Requirement of endogenous
interferon-gamma production for resolution of Listeria monocytogenes infec-
tion. Proc. Natl. Acad. Sci. U.S.A. 82, 7404–7408. doi: 10.1073/pnas.82.
21.7404
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M.,
et al. (2011). STING is a direct innate immune sensor of cyclic di-GMP. Nature
478, 515–518. doi: 10.1038/nature10429
Camejo, A., Carvalho, F., Reis, O., Leitão, E., Sousa, S., and Cabanes, D. (2011). The
arsenal of virulence factors deployed by Listeria monocytogenes to promote its
cell infection cycle. Virulence 2, 379–394. doi: 10.4161/viru.2.5.17703
Carrero, J., and Unanue, E. (2006). Lymphocyte apoptosis as an immune sub-
version strategy of microbial pathogens. Trends Immunol. 27, 497–503. doi:
10.1016/j.it.2006.09.005
Carrero, J. A. (2013). Confounding roles for type I interferons during bacterial and
viral pathogenesis. Int. Immunol. 25, 663–669. doi: 10.1093/intimm/dxt050
Carrero, J. A., Calderon, B., and Unanue, E. R. (2004). Type I interferon sensitizes
lymphocytes to apoptosis and reduces resistance to Listeria infection. J. Exp.
Med. 200, 535–540. doi: 10.1084/jem.20040769
Cartwright, E. J., Jackson, K. A., Johnson, S. D., Graves, L.M., Silk, B. J., andMahon,
B. E. (2013). Listeriosis outbreaks and associated food vehicles, United States,
1998–2008. Emerging Infect. Dis. 19, 1–9. doi: 10.3201/eid1901.120393
Chiba, S., Nagai, T., Hayashi, T., Baba, Y., Nagai, S., and Koyasu, S. (2011). Listerial
invasion protein internalin B promotes entry into ileal Peyer’s patches in vivo.
Microbiol. Immunol. 55, 123–129. doi: 10.1111/j.1348-0421.2010.00292.x
Cole, A. M., Ganz, T., Liese, A. M., Burdick, M. D., Liu, L., and Strieter, R. M.
(2001). Cutting edge: IFN-inducible ELR− CXC chemokines display defensin-
like antimicrobial activity. J. Immunol. 167, 623–627.
Corr, S. C., and O’Neill, L. A. J. (2009). Listeria monocytogenes infection in the
face of innate immunity. Cell. Microbiol. 11, 703–709. doi: 10.1111/j.1462-
5822.2009.01294.x
Cossart, P. (2011). Illuminating the landscape of host-pathogen interactions
with the bacterium Listeria monocytogenes. Proc. Natl. Acad. Sci. U.S.A. 108,
19484–19491. doi: 10.1073/pnas.1112371108
Crimmins, G. T., Herskovits, A. A., Rehder, K., Sivick, K. E., Lauer, P., Dubensky, T.
W., et al. (2008). Listeria monocytogenes multidrug resistance transporters acti-
vate a cytosolic surveillance pathway of innate immunity. Proc. Natl. Acad. Sci.
U.S.A. 105, 10191–10196. doi: 10.1073/pnas.0804170105
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., and Stewart,
T. A. (1993). Multiple defects of immune cell function in mice with dis-
rupted interferon-gamma genes. Science 259, 1739–1742. doi: 10.1126/science.
8456300
de Almeida, L. A., Carvalho, N. B., Oliveira, F. S., Lacerda, T. L. S., Vasconcelos,
A. C., Nogueira, L., et al. (2011). MyD88 and STING signaling pathways are
required for IRF3-mediated IFN-β induction in response to Brucella abortus
infection. PLoS ONE 6:e23135. doi: 10.1371/journal.pone.0023135
Decker, T., Müller, M., and Stockinger, S. (2005). The Yin and Yang of type I
interferon activity in bacterial infection. Nat. Rev. Immunol. 5, 675–687. doi:
10.1038/nri1684
Disson, O., Grayo, S., Huillet, E., Nikitas, G., Langa-Vives, F., Dussurget, O.,
et al. (2008). Conjugated action of two species-specific invasion proteins for
fetoplacental listeriosis. Nature 455, 1114–1118. doi: 10.1038/nature07303
Dortet, L., Mostowy, S., and Cossart, P. (2012). Listeria and autophagy escape:
involvement of InlK, an internalin-like protein. Autophagy 8, 132–134. doi:
10.4161/auto.8.1.18218
Durbin, R. K., Kotenko, S. V., and Durbin, J. E. (2013). Interferon induc-
tion and function at the mucosal surface. Immunol. Rev. 255, 25–39. doi:
10.1111/imr.12101
Fox, B. A., Sheppard, P. O., and O’Hara, P. J. (2009). The role of genomic data in the
discovery, annotation and evolutionary interpretation of the interferon-lambda
family. PLoS ONE 4:e4933. doi: 10.1371/journal.pone.0004933
Freitag, N. E., Port, G. C., and Miner, M. D. (2009). Listeria monocytogenes—
from saprophyte to intracellular pathogen. Nat. Rev. Microbiol. 7, 623–628. doi:
10.1038/nrmicro2171
Gahan, C., and Hill, C. (2005). Gastrointestinal phase of Listeria monocy-
togenes infection. J. Appl. Microbiol. 98, 1345–1353. doi: 10.1111/j.1365-
2672.2005.02559.x
Gao, D., Wu, J., Wu, Y. T., Du, F., Aroh, C., Yan, N., et al. (2013). Cyclic GMP-AMP
synthase is an innate immune sensor of HIV and other retroviruses. Science 341,
903–906. doi: 10.1126/science.1240933
Garifulin, O., Qi, Z., Shen, H., Patnala, S., Green, M. R., and Boyartchuk, V.
(2007). Irf3 polymorphism alters induction of interferon beta in response
to Listeria monocytogenes infection. PLoS Genet. 3:e152. doi: 10.1371/jour-
nal.pgen.0030152
Glimcher, L. H., Townsend, M. J., Sullivan, B. M., and Lord, G. M. (2004). Recent
developments in the transcriptional regulation of cytolytic effector cells. Nat.
Rev. Immunol. 4, 900–911. doi: 10.1038/nri1490
Godfrey, D. I., and Berzins, S. P. (2007). Control points in NKT-cell development.
Nat. Rev. Immunol. 7, 505–518. doi: 10.1038/nri2116
Gouin, E., Adib-Conquy, M., Balestrino, D., Nahori, M.-A., Villiers, V., Colland,
F., et al. (2010). The Listeria monocytogenes InlC protein interferes with innate
immune responses by targeting the IκB kinase subunit IKKα. Proc. Nat. Acad.
Sci. U.S.A. 107, 17333–17338. doi: 10.1073/pnas.1007765107
Goulet, V., Hebert, M., Hedberg, C., Laurent, E., Vaillant, V., De Valk, H.,
et al. (2012). Incidence of listeriosis and related mortality among groups at
risk of acquiring listeriosis. Clin. Infect. Dis. 54, 652–660. doi: 10.1093/cid/
cir902
Hagmann, C. A., Herzner, A. M., Abdullah, Z., Zillinger, T., Jakobs, C., Schuberth,
C., et al. (2013). RIG-I detects triphosphorylated RNA of Listeria monocytogenes
during infection in non-immune cells. PLoS ONE 8:e62872. doi: 10.1371/jour-
nal.pone.0062872
Hamada, S., Umemura, M., Shiono, T., Hara, H., Kishihara, K., Tanaka, K.,
et al. (2008). Importance of murine Vdelta1 gammadelta T cells expressing
interferon-gamma and interleukin-17A in innate protection against Listeria
monocytogenes infection. Immunology 125, 170–177. doi: 10.1111/j.1365-
2567.2008.02841.x
Hamming, O. J., Terczynska-Dyla, E. T. N., Vieyres, G., Dijkman, R., Jorgensen, S.
E., Akhtar, H., et al. (2013). Interferon lambda 4 signals via the IFN-λ recep-
tor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32,
3055–3065. doi: 10.1038/emboj.2013.232
Hamon, M. A., Batsche, E., Regnault, B., Tham, T. N., Seveau, S., Muchardt, C.,
et al. (2007). Histone modifications induced by a family of bacterial toxins. Proc.
Natl. Acad. Sci. U.S.A. 104, 13467–13472. doi: 10.1073/pnas.0702729104
Harty, J. T., and Bevan, M. J. (1995). Specific immunity to Listeria monocytogenes
in the absence of IFN gamma. Immunity 3, 109–117. doi: 10.1016/1074-
7613(95)90163-9
Heim, M. H. (2013). 25 years of interferon-based treatment of chronic hepati-
tis C: an epoch coming to an end. Nat. Rev. Immunol. 13, 535–542. doi:
10.1038/nri3463
Henry, T., Kirimanjeswara, G. S., Ruby, T., Jones, J. W., Peng, K., Perret, M.,
et al. (2010). Type I IFN signaling constrains IL-17A/F secretion by gamma-
delta T cells during bacterial infections. J. Immunol. 184, 3755–3767. doi:
10.4049/jimmunol.0902065
Hermant, P., Demarez, C., Mahlakõiv, T., Staeheli, P., Meuleman, P., and Michiels,
T. (2014). Human but not mouse hepatocytes respond to interferon-lambda
in vivo. PLoS ONE 9:e87906. doi: 10.1371/journal.pone.0087906
Hoelzer, K., Pouillot, R., and Dennis, S. (2012). Animal models of listeriosis: a com-
parative review of the current state of the art and lessons learned. Vet. Res. 43:18.
doi: 10.1186/1297-9716-43-18
Holland, S. M. (2010). Chronic granulomatous disease. Clin. Rev. Allerg. Immunol.
38, 3–10. doi: 10.1007/s12016-009-8136-z
Honda, K., Takaoka, A., and Taniguchi, T. (2006). Type I interferon gene induction
by the interferon regulatory factor family of transcription factors. Immunity 25,
349–360. doi: 10.1016/j.immuni.2006.08.009
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 9
Dussurget et al. Listeria and interferons
Honda, K., Yanai, H., Negishi, H., Asagiri, M., Sato, M., Mizutani, T., et al. (2005).
IRF-7 is themaster regulator of type-I interferon-dependent immune responses.
Nature 434, 772–777. doi: 10.1038/nature03464
Hu, X., and Ivashkiv, L. B. (2009). Cross-regulation of signaling pathways by
interferon-gamma: implications for immune responses and autoimmune dis-
eases. Immunity 31, 539–550. doi: 10.1016/j.immuni.2009.09.002
Huang, S., Hendriks, W., Althage, A., Hemmi, S., Bluethmann, H., Kamijo, R.,
et al. (1993). Immune response inmice that lack the interferon-gamma receptor.
Science 259, 1742–1745. doi: 10.1126/science.8456301
Isaacs, A., and Lindemann, J. (1957). Virus Interference. I. The Interferon. Proc.
Royal. Soc. B Biol. Sci. 147, 258–267. doi: 10.1098/rspb.1957.0048
Iversen, M. B., and Paludan, S. R. (2010). Mechanisms of type III interferon
expression. J. Interferon Cytokine Res. 30, 573–578. doi: 10.1089/jir.2010.0063
Jia, T., Leiner, I., Dorothee, G., Brandl, K., and Pamer, E. G. (2009). MyD88
and Type I interferon receptor-mediated chemokine induction and mono-
cyte recruitment during Listeria monocytogenes infection. J. Immunol. 183,
1271–1278. doi: 10.4049/jimmunol.0900460
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J. F., Newport, M.,
et al. (1996). Interferon-gamma-receptor deficiency in an infant with fatal
bacille Calmette-Guérin infection. N. Engl. J. Med. 335, 1956–1961. doi:
10.1056/NEJM199612263352604
Jouanguy, E., Döffinger, R., Dupuis, S., Pallier, A., Altare, F., and Casanova,
J.-L. (1999). IL-12 and IFN-gamma in host defense against mycobacteria
and salmonella in mice and men. Curr. Opin. Immunol. 11, 346–351. doi:
10.1016/S0952-7915(99)80055-7
Kamijo, R., Le, J., Shapiro, D., Havell, E. A., Huang, S., Aguet, M., et al.
(1993). Mice that lack the interferon-gamma receptor have profoundly altered
responses to infection with Bacillus Calmette-Guérin and subsequent challenge
with lipopolysaccharide. J. Exp. Med. 178, 1435–1440. doi: 10.1084/jem.178.
4.1435
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., et al.
(1998). Demonstration of an interferon gamma-dependent tumor surveillance
system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A. 95, 7556–7561.
doi: 10.1073/pnas.95.13.7556
Kearney, S. J., Delgado, C., Eshleman, E. M., Hill, K. K., O’Connor, B. P., and Lenz,
L. L. (2013). Type I IFNs downregulate myeloid cell IFN-gamma receptor by
inducing recruitment of an early growth response 3/NGFI-A binding protein
1 complex that silences ifngr1 transcription. J. Immunol. 191, 3384–3392. doi:
10.4049/jimmunol.1203510
Kernbauer, E., Maier, V., Rauch, I., Müller, M., and Decker, T. (2013). Route of
infection determines the impact of type I interferons on innate immunity to
Listeria monocytogenes. PLoS ONE 8:e65007. doi: 10.1371/journal.pone.0065007
Kernbauer, E., Maier, V., Stoiber, D., Strobl, B., Schneckenleithner, C., Sexl, V., et al.
(2012). Conditional Stat1 ablation reveals the importance of interferon signal-
ing for immunity to Listeria monocytogenes infection. PLoS Pathog. 8:e1002763.
doi: 10.1371/journal.ppat.1002763
Kim, B.-H., Shenoy, A. R., Kumar, P., Das, R., Tiwari, S., and MacMicking, J.
D. (2011). A family of IFN-gamma-inducible 65-kD GTPases protects against
bacterial infection. Science 332, 717–721. doi: 10.1126/science.1201711
Kotenko, S. V. (2011). IFN-λs. Curr. Opin. Immunol. 23, 583–590. doi:
10.1016/j.coi.2011.07.007
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N.
K., et al. (2003). IFN-λs mediate antiviral protection through a distinct class II
cytokine receptor complex. Nat. Immunol. 4, 69–77. doi: 10.1038/ni875
Lazarevic, V., Glimcher, L. H., and Lord, G. M. (2013). T-bet: a bridge
between innate and adaptive immunity. Nat. Rev. Immunol. 13, 777–789. doi:
10.1038/nri3536
Lebreton, A., Cossart, P., and Bierne, H. (2012). Bacteria tune interferon responses
by playing with chromatin. Virulence 3, 87–91. doi: 10.4161/viru.3.1.18531
Lebreton, A., Job, V., Ragon, M., Le Monnier, A., Dessen, A., Cossart, P.,
et al. (2014). Structural basis for the inhibition of the chromatin repres-
sor BAHD1 by the bacterial nucleomodulin LntA. MBio. 5:e00775-13.
doi:10.1128/mBio.00775-13
Lebreton, A., Lakisic, G., Job, V., Fritsch, L., Tham, T. N., Camejo, A., et al.
(2011). A bacterial protein targets the BAHD1 chromatin complex to stimu-
late type III interferon response. Science 331, 1319–1321. doi: 10.1126/science.
1200120
Lecuit, M. (2007). Human listeriosis and animal models. Microbes Infect. 9,
1216–1225. doi: 10.1016/j.micinf.2007.05.009
Lecuit, M., Vandormael-Pournin, S., Lefort, J., Huerre, M., Gounon, P., Dupuy, C.,
et al. (2001). A transgenic model for listeriosis: role of internalin in crossing the
intestinal barrier. Science 292, 1722–1725. doi: 10.1126/science.1059852
Levy, D. E., Marié, I. J., and Durbin, J. E. (2011). Induction and function of type I
and III interferon in response to viral infection. Curr. Opin. Virol. 1, 476–486.
doi: 10.1016/j.coviro.2011.11.001
Lipinski, S., Till, A., Sina, C., Arlt, A., Grasberger, H., Schreiber, S., et al. (2009).
DUOX2-derived reactive oxygen species are effectors of NOD2-mediated
antibacterial responses. J. Cell Sci. 122, 3522–3530. doi: 10.1242/jcs.050690
Lorber, B. (1997). Listeriosis. Clin. Infect. Dis. 24, 1–9. doi: 10.1093/clinids/24.1.1
Mackaness, G. B. (1962). Cellular resistance to infection. J. Exp. Med. 116, 381–406.
doi: 10.1084/jem.116.3.381
MacMicking, J. D. (2004). IFN-inducible GTPases and immunity to intracellular
pathogens. Trends Immunol. 25, 601–609. doi: 10.1016/j.it.2004.08.010
MacMicking, J. D. (2012). Interferon-inducible effector mechanisms in cell-
autonomous immunity. Nat. Rev. Immunol. 12, 367–382. doi: 10.1038/nri3210
Malireddi, R. K. S., and Kanneganti, T.-D. (2013). Role of type I interferons in
inflammasome activation, cell death, and disease during microbial infection.
Front. Cell. Infect. Microbiol. 3:77. doi: 10.3389/fcimb.2013.00077
Mancuso, G., Midiri, A., Biondo, C., Beninati, C., Zummo, S., Galbo, R., et al.
(2007). Type I IFN signaling is crucial for host resistance against different species
of pathogenic bacteria. J. Immunol. 178, 3126–3133.
Marçais, A., Viel, S., Grau, M., Henry, T., Marvel, J., and Walzer, T. (2013).
Regulation of mouse NK cell development and function by cytokines. Front.
Immunol. 4:450. doi: 10.3389/fimmu.2013.00450
Marcello, T., Grakoui, A., Barba Spaeth, G., Machlin, E. S., Kotenko, S. V.,
Macdonald, M. R., et al. (2006). Interferons α and λ inhibit hepatitis C
virus replication with distinct signal transduction and gene regulation kinetics.
Gastroenterology 131, 1887–1898. doi: 10.1053/j.gastro.2006.09.052
Martin, F. J., Gomez, M. I., Wetzel, D. M., Memmi, G., O’Seaghdha, M., Soong, G.,
et al. (2009). Staphylococcus aureus activates type I IFN signaling in mice and
humans through the Xr repeated sequences of protein A. J. Clin. Invest. 119,
1931–1939. doi: 10.1172/JCI35879
McCaffrey, R. L., Fawcett, P., O’Riordan, M., Lee, K.-D., Havell, E. A., Brown, P. O.,
et al. (2004). A specific gene expression program triggered by Gram-positive
bacteria in the cytosol. Proc. Natl. Acad. Sci. U.S.A. 101, 11386–11139. doi:
10.1073/pnas.0403215101
Monroe, K. M., McWhirter, S. M., and Vance, R. E. (2010). Induction of type
I interferons by bacteria. Cell. Microbiol. 12, 881–890. doi: 10.1111/j.1462-
5822.2010.01478.x
Mordstein, M., Michiels, T., and Staeheli, P. (2010). What have we learned from
the IL28 receptor knockout mouse? J. Interferon Cytokine Res. 30, 579–584. doi:
10.1089/jir.2010.0061
Myers, J. T., Tsang, A. W., and Swanson, J. A. (2003). Localized reactive oxygen and
nitrogen intermediates inhibit escape of Listeria monocytogenes from vacuoles
in activated macrophages. J. Immunol. 171, 5447–5453.
Newman, K. C., and Riley, E. M. (2007). Whatever turns you on: accessory-cell-
dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 7, 279–291.
doi: 10.1038/nri2057
Newport, M. J., Huxley, C. M., Huston, S., Hawrylowicz, C. M., Oostra, B. A.,
Williamson, R., et al. (1996). A mutation in the interferon-gamma-receptor
gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335,
1941–1949. doi: 10.1056/NEJM199612263352602
Nikitas, G., Deschamps, C., Disson, O., Niault, T., Cossart, P., and Lecuit,M. (2011).
Transcytosis of Listeria monocytogenes across the intestinal barrier upon specific
targeting of goblet cell accessible E-cadherin. J. Exp. Med. 208, 2263–2277. doi:
10.1084/jem.20110560
O’Connell, R. M., Saha, S. K., Vaidya, S. A., Bruhn, K. W., Miranda, G. A.,
Zarnegar, B., et al. (2004). Type I interferon production enhances susceptibility
to Listeria monocytogenes infection. J. Exp. Med. 200, 437–445. doi: 10.1084/jem.
20040712
O’Connell, R. M., Vaidya, S. A., Perry, A. K., Saha, S. K., Dempsey, P. W., and
Cheng, G. (2005). Immune activation of type I IFNs by Listeria monocytogenes
occurs independently of TLR4, TLR2, and receptor interacting protein 2 but
involves TNFR-associated NF kappa B kinase-binding kinase 1. J. Immunol. 174,
1602–1607.
Okamoto, M. (1994). Host defense and endogenous interferon-gamma in the
intestines during an oral infection with Listeria monocytogenes. Hokkaido Igaku
Zasshi 69, 794–809.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 10
Dussurget et al. Listeria and interferons
Ooi, S. T., and Lorber, B. (2005). Gastroenteritis due to Listeria monocytogenes.Clin.
Infect. Dis. 40, 1327–1332. doi: 10.1086/429324
O’Riordan,M., Yi, C. H., Gonzales, R., Lee, K.-D., and Portnoy, D. A. (2002). Innate
recognition of bacteria by a macrophage cytosolic surveillance pathway. Proc.
Natl. Acad. Sci. U.S.A. 99, 13861–13866. doi: 10.1073/pnas.202476699
Panne, D. (2008). The enhanceosome. Curr. Opin. Struct. Biol. 18, 236–242. doi:
10.1016/j.sbi.2007.12.002
Panne, D., Maniatis, T., and Harrison, S. C. (2007). An atomic model
of the interferon-beta enhanceosome. Cell 129, 1111–1123. doi:
10.1016/j.cell.2007.05.019
Parvatiyar, K., Zhang, Z., Teles, R. M., Ouyang, S., Jiang, Y., Iyer, S. S., et al. (2012).
The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-
GMP and cyclic di-AMP to activate a type I interferon immune response. Nat.
Immunol. 13, 1155–1161. doi: 10.1038/ni.2460
Patel, A. A., Lee-Lewis, H., Hughes-Hanks, J., Lewis, C. A., and Anderson, D. M.
(2012). Opposing roles for interferon regulatory factor-3 (IRF-3) and type I
interferon signaling during plague. PLoS Pathog. 8:e1002817. doi: 10.1371/jour-
nal.ppat.1002817
Pentecost, M., Otto, G., Theriot, J. A., and Amieva, M. R. (2006). Listeria monocyto-
genes invades the epithelial junctions at sites of cell extrusion. PLoS Pathog. 2:e3.
doi: 10.1371/journal.ppat.0020003
Personnic, N., Bruck, S., Nahori, M.-A., Toledo-Arana, A., Nikitas, G., Lecuit, M.,
et al. (2010). The stress-induced virulence protein InlH controls interleukin-
6 production during murine listeriosis. Infect. Immun. 78, 1979–1989. doi:
10.1128/IAI.01096-09
Pestka, S. (2007). The interferons: 50 years after their discovery, there is much more
to learn. J. Biol. Chem. 282, 20047–20051. doi: 10.1074/jbc.R700004200
Pestka, S., Krause, C. D., and Walter, M. R. (2004). Interferons, interferon-like
cytokines, and their receptors. Immunol. Rev. 202, 8–32. doi: 10.1111/j.0105-
2896.2004.00204.x
Piehler, J., Thomas, C., Garcia, K. C., and Schreiber, G. (2012). Structural and
dynamic determinants of type I interferon receptor assembly and their func-
tional interpretation. Immunol. Rev. 250, 317–334. doi: 10.1111/imr.12001
Pietilä, T. E., Latvala, S., Osterlund, P., and Julkunen, I. (2010). Inhibition of
dynamin-dependent endocytosis interferes with type III IFN expression in
bacteria-infected human monocyte-derived DCs. J. Leukoc. Biol. 88, 665–674.
doi: 10.1189/jlb.1009651
Pontiroli, F., Dussurget, O., Zanoni, I., Urbano, M., Beretta, O., Granucci, F., et al.
(2012). The timing of IFNβ production affects early innate responses to Listeria
monocytogenes and determines the overall outcome of lethal infection. PLoS
ONE 7:e43455. doi: 10.1371/journal.pone.0043455
Popov, A., Abdullah, Z.,Wickenhauser, C., Saric, T., Driesen, J., Hanisch, F.-G., et al.
(2006). Indoleamine 2,3-dioxygenase–expressing dendritic cells form suppura-
tive granulomas following Listeria monocytogenes infection. J. Clin. Invest. 116,
3160–3170. doi: 10.1172/JCI28996
Prokunina-Olsson, L., Muchmore, B., Tang, W., Pfeiffer, R. M., Park, H.,
Dickensheets, H., et al. (2013). A variant upstream of IFNL3 (IL28B) creating
a new interferon gene IFNL4 is associated with impaired clearance of hepatitis
C virus. Nat. Genet. 45, 164–171. doi: 10.1038/ng.2521
Qiu, H., Fan, Y., Joyee, A. G., Wang, S., Han, X., Bai, H., et al. (2008). Type I IFNs
enhance susceptibility to Chlamydia muridarum lung infection by enhancing
apoptosis of local macrophages. J. Immunol. 181, 2092–2102.
Rae, C. S., Geissler, A., Adamson, P. C., and Portnoy, D. A. (2011). Mutations
of the Listeria monocytogenes peptidoglycan N-deacetylase and O-acetylase
result in enhanced lysozyme sensitivity, bacteriolysis, and hyperinduction of
innate immune pathways. Infect. Immun. 79, 3596–3606. doi: 10.1128/IAI.
00077-11
Rayamajhi, M., Humann, J., Kearney, S., Hill, K. K., and Lenz, L. L.
(2010). Antagonistic crosstalk between type I and II interferons and
increased host susceptibility to bacterial infections. Virulence 1, 418–422. doi:
10.4161/viru.1.5.12787
Reutterer, B., Stockinger, S., Pilz, A., Soulat, D., Kastner, R., Westermayer, S.,
et al. (2008). Type I IFN are host modulators of strain-specific Listeria
monocytogenes virulence. Cell. Microbiol. 10, 1116–1129. doi: 10.1111/j.1462-
5822.2007.01114.x
Reynders, A., Yessaad, N., Vu Manh, T.-P., Dalod, M., Fenis, A., Aubry, C., et al.
(2011). Identity, regulation and in vivo function of gut NKp46(+)RORγt(+)
and NKp46(+)RORγt(-) lymphoid cells. EMBO J. 30, 2934–2947. doi:
10.1038/emboj.2011.201
Robinson, N., McComb, S., Mulligan, R., Dudani, R., Krishnan, L., and Sad, S.
(2012). Type I interferon induces necroptosis in macrophages during infection
with Salmonella enterica serovar Typhimurium.Nat. Immunol. 13, 954–962. doi:
10.1038/ni.2397
Roesler, J., Kofink, B., Wendisch, J., Heyden, S., Paul, D., Friedrich, W., et al. (1999).
Listeria monocytogenes and recurrent mycobacterial infections in a child with
complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational
analysis and evaluation of therapeutic options. Exp. Hematol. 27, 1368–1374.
doi: 10.1016/S0301-472X(99)00077-6
Rusinova, I., Forster, S., Yu, S., Kannan, A., Masse, M., Cumming, H., et al. (2012).
Interferome v2.0: an updated database of annotated interferon-regulated genes.
Nucleic Acids Res. 41, 1040–1046. doi: 10.1093/nar/gks1215
Samten, B., Townsend, J. C., Weis, S. E., Bhoumik, A., Klucar, P., Shams, H., et al.
(2008). CREB, ATF, and AP-1 transcription factors regulate IFN-gamma secre-
tion by human T cells in response to mycobacterial antigen. J. Immunol. 181,
2056–2064.
Sauer, J.-D., Sotelo-Troha, K., von Moltke, J., Monroe, K. M., Rae, C. S., Brubaker,
S. W., et al. (2011). The ENU-induced Goldenticket mouse mutant reveals
an essential function of Sting in the in vivo interferon response to Listeria
monocytogenes and cyclic-di-nucleotides. Infect. Immun. 79, 688–694. doi:
10.1128/IAI.00999-10
Schindler, C., Levy, D. E., and Decker, T. (2007). JAK-STAT signaling: from interfer-
ons to cytokines. J. Biol. Chem. 282, 20059–20063. doi: 10.1074/jbc.R700016200
Schlech, W. F., Lavigne, P. M., Bortolussi, R. A., Allen, A. C., Haldane, E. V., Wort,
A. J., et al. (1983). Epidemic listeriosis: evidence for transmission by food. N.
Engl. J. Med. 308, 203–206. doi: 10.1056/NEJM198301273080407
Schoenborn, J. R., and Wilson, C. B. (2007). Regulation of interferon-γ dur-
ing innate and adaptive immune responses. Adv. Immunol. 96, 41–101. doi:
10.1016/S0065-2776(07)96002-2
Schoggins, J. W., MacDuff, D. A., Imanaka, N., Gainey, M. D., Shrestha, B., Eitson,
J. L., et al. (2014). Pan-viral specificity of IFN-induced genes reveals new roles
for cGAS in innate immunity. Nature 505, 691–695. doi: 10.1038/nature12862
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz,
P., et al. (2011). A diverse range of gene products are effectors of the type I
interferon antiviral response. Nature 472, 481–485. doi: 10.1038/nature09907
Schroder, K. (2003). Interferon-gamma: an overview of signals, mechanisms and
functions. J. Leukoc. Biol. 75, 163–189. doi: 10.1189/jlb.0603252
Schwartz, K. T., Carleton, J. D., Quillin, S. J., Rollins, S. D., Portnoy, D. A., and Leber,
J. H. (2012). Hyperinduction of host beta interferon by a Listeria monocytogenes
strain naturally overexpressing themultidrug efflux pumpMdrT. Infect. Immun.
80, 1537–1545. doi: 10.1128/IAI.06286-11
Shaughnessy, L. M., and Swanson, J. A. (2007). The role of the activated
macrophage in clearing Listeria monocytogenes infection. Front. Biosci 12,
2683–2692. doi: 10.2741/2364
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore,
T. E., et al. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat.
Immunol. 4, 63–68. doi: 10.1038/ni873
Shi, C., and Pamer, E. G. (2011). Monocyte recruitment during infection and
inflammation. Nat. Rev. Immunol. 11, 762–774. doi: 10.1038/nri3070
Sonoda, J., Laganiere, J., Mehl, I. R., Barish, G. D., Chong, L.-W., Li, X., et al.
(2007). Nuclear receptor ERR-alpha and coactivator PGC-1beta are effec-
tors of IFN-gamma-induced host defense. Genes Dev. 21, 1909–1920. doi:
10.1101/gad.1553007
Stavru, F., Archambaud, C., and Cossart, P. (2011). Cell biology and immunology
of Listeria monocytogenes infections: novel insights. Immunol. Rev. 240, 160–184.
doi: 10.1111/j.1600-065X.2010.00993.x
Stetson, D., and Medzhitov, R. (2006). Type I interferons in host defense. Immunity
25, 373–381. doi: 10.1016/j.immuni.2006.08.007
Stockinger, S., Kastner, R., Kernbauer, E., Pilz, A., Westermayer, S., Reutterer, B.,
et al. (2009). Characterization of the interferon-producing cell in mice infected
with Listeria monocytogenes. PLoS Pathog. 5:e1000355. doi: 10.1371/jour-
nal.ppat.1000355
Stockinger, S., Reutterer, B., Schaljo, B., Schellack, C., Brunner, S., Materna, T.,
et al. (2004). IFN regulatory factor 3-dependent induction of type I IFNs by
intracellular bacteria is mediated by a TLR- andNod2-independent mechanism.
J. Immunol. 173, 7416–7425.
Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z. J. (2013). Cyclic GMP-AMP synthase
is a cytosolic DNA sensor that activates the type I interferon pathway. Science
339, 786–791. doi: 10.1126/science.1232458
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 11
Dussurget et al. Listeria and interferons
Swaminathan, B., and Gernersmidt, P. (2007). The epidemiology of human liste-
riosis. Microbes Infect. 9, 1236–1243. doi: 10.1016/j.micinf.2007.05.011
Tailor, P., Tamura, T., Kong, H. J., Kubota, T., Kubota, M., Borghi, P., et al.
(2007). The feedback phase of type I interferon induction in dendritic
cells requires interferon regulatory factor 8. Immunity 27, 228–239. doi:
10.1016/j.immuni.2007.06.009
Thale, C., and Kiderlen, A. (2005). Sources of interferon-gamma in early
immune response to Listeria monocytogenes. Immunobiol 210, 673–683. doi:
10.1016/j.imbio.2005.07.003
Toledo-Arana, A., Dussurget, O., Nikitas, G., Sesto, N., Guet-Revillet, H.,
Balestrino, D., et al. (2009). The Listeria transcriptional landscape from sapro-
phytism to virulence. Nature 459, 950–956. doi: 10.1038/nature08080
Trinchieri, G. (2010). Type I interferon: friend or foe? J. Exp. Med. 207, 2053–2063.
doi: 10.1084/jem.20101664
van de Vosse, E., van Dissel, J. T., and Ottenhoff, T. H. (2009). Genetic deficiencies
of innate immune signalling in human infectious disease. Lancet Infect. Dis. 9,
688–698. doi: 10.1016/S1473-3099(09)70255-5
van Pesch, V., Lanaya, H., Renauld, J. C., and Michiels, T. (2004). Characterization
of the murine alpha interferon gene family. J. Virol. 78, 8219–8228. doi:
10.1128/JVI.78.15.8219-8228.2004
Vázquez-Boland, J. A., Kuhn, M., Berche, P., Chakraborty, T., Domínguez-Bernal,
G., Goebel, W., et al. (2001). Listeria pathogenesis and molecular virulence
determinants. Clin. Microbiol. Rev. 14, 584–640. doi: 10.1128/CMR.14.3.584-
640.2001
Walters, K.-A., Joyce, M. A., Thompson, J. C., Smith, M. W., Yeh, M. M., Proll, S.,
et al. (2006). Host-specific response to HCV infection in the chimeric SCID-
beige/Alb-uPA mouse model: role of the innate antiviral immune response.
PLoS Pathog. 2:e59. doi: 10.1371/journal.ppat.0020059
Watanabe, T., Asano, N., Fichtner-Feigl, S., Gorelick, P. L., Tsuji, Y., Matsumoto,
Y., et al. (2010). NOD1 contributes to mouse host defense against Helicobacter
pylori via induction of type I IFN and activation of the ISGF3 signaling pathway.
J. Clin. Invest. 120, 1645–1662. doi: 10.1172/JCI39481
Wheelock, E. F., and Sibley,W. A. (1965). Circulating virus, interferon and antibody
after vaccination with the 17-D strain of yellow-fever virus.N. Engl. J. Med. 273,
194–198. doi: 10.1056/NEJM196507222730404
Wilson, C. B., and Brooks, D. G. (2013). Decoding the complexity of type I inter-
feron to treat persistent viral infections. Trends Microbiol. 21, 634–640. doi:
10.1016/j.tim.2013.10.003
Wilson, C. B., Rowell, E., and Sekimata, M. (2009). Epigenetic control of T-helper-
cell differentiation. Nat. Rev. Immunol. 9, 91–105. doi: 10.1038/nri2487
Witte, C. E., Archer, K. A., Rae, C. S., Sauer, J.-D., Woodward, J. J., and Portnoy,
D. A. (2012). Innate immune pathways triggered by Listeria monocytogenes
and their role in the induction of cell-mediated immunity. Adv. Immunol. 113,
135–156. doi: 10.1016/B978-0-12-394590-7.00002-6
Woodward, J. J., Iavarone, A. T., and Portnoy, D. A. (2010). c-di-AMP secreted by
intracellular Listeria monocytogenes activates a host type I interferon response.
Science 328, 1703–1705. doi: 10.1126/science.1189801
Wu, J., Sun, L., Chen, X., Du, F., Shi, H., Chen, C., et al. (2013). Cyclic GMP-AMP
is an endogenous second messenger in innate immune signaling by cytosolic
DNA. Science 339, 826–830. doi: 10.1126/science.1229963
Yamamoto, T., Hara, H., Tsuchiya, K., Sakai, S., Fang, R., Matsuura, M., et al.
(2012). Listeria monocytogenes strain-specific impairment of the TetR regulator
underlies the drastic increase in cyclic di-AMP secretion and beta interferon-
inducing ability. Infect. Immun. 80, 2323–2332. doi: 10.1128/IAI.06162-11
Yang, P., An, H., Liu, X., Wen, M., Zheng, Y., Rui, Y., et al. (2010). The cytosolic
nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a
β-catenin-dependent pathway.Nat. Immunol. 11, 487–494. doi: 10.1038/ni.1876
Zenewicz, L., and Shen, H. (2007). Innate and adaptive immune responses to
Listeria monocytogenes: a short overview. Microbes Infect. 9, 1208–1215. doi:
10.1016/j.micinf.2007.05.008
Zheng, Y.-W., Li, H., Yu, J.-P., Zhao, H., Wang, S. E., and Ren, X.-B. (2013).
Interferon-λs: special immunomodulatory agents and potential therapeutic
targets. J. Innate Immun. 5, 209–218. doi: 10.1159/000345365
Zwaferink, H., Stockinger, S., Reipert, S., and Decker, T. (2007). Stimulation of
inducible nitric oxide synthase expression by beta interferon increases necrotic
death of macrophages upon Listeria monocytogenes infection. Infect. Immun.
76, 1649–1656. doi: 10.1128/IAI.01251-07
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 05 February 2014; accepted: 04 April 2014; published online: 28 April 2014.
Citation: Dussurget O, Bierne H and Cossart P (2014) The bacterial pathogen Listeria
monocytogenes and the interferon family: type I, type II and type III interferons. Front.
Cell. Infect. Microbiol. 4:50. doi: 10.3389/fcimb.2014.00050
This article was submitted to the journal Frontiers in Cellular and Infection
Microbiology.
Copyright © 2014 Dussurget, Bierne and Cossart. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this jour-
nal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Cellular and Infection Microbiology www.frontiersin.org April 2014 | Volume 4 | Article 50 | 12
